受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:A2013 Batch: A201308
Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
CAS No. | 1428935-60-7 |
---|---|
Formulation | PBS buffer, pH 7.2 |
Isotype | Human IgG1 |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Shipping | Shipped under low temperature conditions |
Purity | 99% |
Protein concentration | 5.99mg/ml |
Endotoxin Level | <1EU/mg |
Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker [ J Biol Chem, 2024, S0021-9258(24)01826-X] | PubMed: 38685532 |
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] | PubMed: 38500749 |
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] | PubMed: 38500749 |
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer [ Heliyon, 2023, 9(6):e15782] | PubMed: 37389074 |
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune [ Heliyon, 2023, 9(6):e15782.] | PubMed: 37389074 |
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor [ Cancer Discov, 2022, 12(6):1482-1499] | PubMed: 35254416 |
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor [ Cancer Discov, 2022, 12(6):1482-1499] | PubMed: 35254416 |
SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling [ J Med Chem, 2022, 65(5):3879-3893] | PubMed: 35188766 |
Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells [ Mol Pharm, 2022, 10.1021/acs.molpharmaceut.2c00084] | PubMed: 35244407 |
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer [ Cancer Commun (Lond), 2021, 41(6):511-527] | PubMed: 33939321 |
人間や獣医の診断であるか治療的な使用のためにでない。